"Neutropenia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A decrease in the number of NEUTROPHILS found in the blood.
Below are MeSH descriptors whose meaning is more general than "Neutropenia".
Below are MeSH descriptors whose meaning is more specific than "Neutropenia".
This graph shows the total number of publications written about "Neutropenia" by people in Harvard Catalyst Profiles by year, and whether "Neutropenia" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 4 | 9 | 13 |
1995 | 5 | 6 | 11 |
1996 | 4 | 11 | 15 |
1997 | 3 | 9 | 12 |
1998 | 6 | 4 | 10 |
1999 | 6 | 7 | 13 |
2000 | 6 | 18 | 24 |
2001 | 3 | 10 | 13 |
2002 | 3 | 13 | 16 |
2003 | 4 | 6 | 10 |
2004 | 3 | 11 | 14 |
2005 | 6 | 14 | 20 |
2006 | 7 | 10 | 17 |
2007 | 7 | 7 | 14 |
2008 | 7 | 5 | 12 |
2009 | 13 | 5 | 18 |
2010 | 10 | 15 | 25 |
2011 | 8 | 8 | 16 |
2012 | 8 | 10 | 18 |
2013 | 5 | 7 | 12 |
2014 | 5 | 9 | 14 |
2015 | 8 | 11 | 19 |
2016 | 8 | 5 | 13 |
2017 | 9 | 19 | 28 |
2018 | 6 | 9 | 15 |
2019 | 11 | 11 | 22 |
2020 | 7 | 3 | 10 |
2021 | 15 | 4 | 19 |
2022 | 14 | 4 | 18 |
2023 | 22 | 2 | 24 |
2024 | 6 | 0 | 6 |
Below are the most recent publications written about "Neutropenia" by people in Profiles.
-
CRE24-042: Microgranular Acute Promyelocytic Leukemia Presenting as Recurrent Stroke and Isolated Neutropenia. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5).
-
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study. Oncologist. 2024 Apr 04; 29(4):303-310.
-
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study. Haematologica. 2024 Mar 01; 109(3):867-876.
-
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study. Haematologica. 2024 Mar 01; 109(3):895-905.
-
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024 Apr; 99(4):615-624.
-
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024 Feb 01; 143(5):404-416.
-
Efficacy of Cetuximab Combined with Paclitaxel in Patients with Recurrent Salivary Gland Carcinoma: A Retrospective Observational Study. ORL J Otorhinolaryngol Relat Spec. 2024; 86(1):41-49.
-
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. J Clin Oncol. 2024 Apr 01; 42(10):1146-1157.
-
Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047). Neuro Oncol. 2023 12 08; 25(12):2262-2272.
-
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER study. Future Oncol. 2023 Nov; 19(35):2341-2348.